Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …

Respiratory symptoms are ubiquitous and impair health-related quality of life in people with
respiratory disease. This European Respiratory Society (ERS) task force aimed to provide …

Idiopathic pulmonary fibrosis (IPF) and other forms of fibrosing interstitial lung disease (F-
ILD) are life-altering conditions that insinuate themselves into patients' lives and thrust upon …

Background In fibrotic interstitial lung diseases, exertional breathlessness is strongly linked
to health-related quality of life (HRQOL). Breathlessness is often associated with oxygen …

Pulmonary complications in CTD are common and can involve the interstitium, airways,
pleura and pulmonary vasculature. ILD can occur in all CTD (CTD‐ILD), and may vary from …

Breathlessness, dyspnoea and shortness of breath are synonymous terms to describe the
'subjective experience of breathing discomfort that consists of qualitatively distinct …

Background Idiopathic pulmonary fibrosis (IPF) is characterised by worsening dyspnoea and
exercise intolerance. Research question Does a long-term pulmonary rehabilitation improve …

Patients with interstitial lung diseases (ILD) often have hypoxemia at rest and/or with
exertion, for which supplemental oxygen is commonly prescribed. The number of patients …

Progressive pulmonary fibrosis (PF) is a complex interstitial lung disease that impacts
substantially on patients' daily lives, requiring personalised and integrated care. We …

Some chronic respiratory diseases can cause hypoxemia and, in such cases, long-term
home oxygen therapy (LTOT) is indicated as a treatment option primarily to improve patient …